Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Samsung BioLogics' New Plant Approved by FDA

publication date: Oct 12, 2017

Samsung BioLogics, a Korean biologics CMO, received US FDA approval to produce an antibody drug substance at its second plant. The second facility, currently Samsung's largest, was completed in March 2016. Samsung has a larger $740 million third plant scheduled to complete its construction by the end of this year. The company has two divisions: a biologics CMO and Bioepis, a joint venture with Biogen that makes biosimilars. In 2016, Samsung completed a $2 billion IPO in South Korea. More details....

Stock Symbols: (KRX: 207940) (NSDQ: BIIB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.